ATOS — Atossa Therapeutics Share News
0.000.00%
Last trade - 00:00Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Atossa Therapeutics Announces Positive FDA Feedback, Advances Toward Ind For (Z)-Endoxifen Clinical Program In Er+/Her2- Metastatic Breast Cancer
Atossa Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
SEC Filing
Atossa Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses
Brief: Atos estimates year-end liquidity at EUR 2.19 billion
Brief: Atossa Therapeutics- Enters Open Market Sale Agreement To Sell Shares Of Common Stock Of Up To $100 Million From Time To Time - SEC Filing
Atossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Atossa Therapeutics Announces Support Of Final Rule From FDA Requiring Patient Notification Of Breast Density
Brief: Atossa Therapeutics Granted Additional Patent Protection For Endoxifen
Brief: Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer
Atossa Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Atossa Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview
Brief: Atossa Completes Enrollment Of 80Mg Pharmacokinetic Run-In Cohort In Phase 2 Evangeline Clinical Trial